Intra Cellular Therapies reported $-72491000 in EBITDA for its first fiscal quarter of 2022.

Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
Ebitda Change
Acadia Pharmaceuticals ACAD:US $ -112.5M 68.38M
ALKERMES ALKS:US $ -7.39M 30.91M
Aptinyx Inc APTX:US $ -19279000 207K
Biocryst Pharmaceuticals BCRX:US $ -49.64M 2.37M
Biogen BIIB:US $ 674.7M 20.2M
Bristol Myers Squibb BMY:US $ 5772M 404M
Cytokinetics CYTK:US $ -76.52M 58.35M
Esperion Therapeutics ESPR:US $ -42836000 611K
Gilead Sciences GILD:US $ 3422M 1947M
Halozyme Therapeutics HALO:US $ 76.45M 19.11M
Intra Cellular Therapies ITCI:US $ -72.49M 13.37M
JAZZ PHA JAZZ:US $ 267.26M 90.66M
Johnson & Johnson JNJ:US $ 9309M 1549M
Marinus Pharmaceuticals MRNS:US $ -16.63M 10.4M
Minerva Neurosciences NERV:US $ -7.99M 13.39M
Nektar Therapeutics NKTR:US $ -111.36M 1.88M
Neurocrine Biosciences NBIX:US $ 6.4M 60.6M
Novartis NVS:US $ 4552M 346M
Prothena PRTA:US -37744000 4.89M
Supernus Pharmaceuticals SUPN:US $ 23.33M 17.79M
United Therapeutics UTHR:US $ 300.5M 117.1M
Vanda Pharmaceuticals VNDA:US $ -6.97M 36.11M